Diversified Trust Co Has $12.05 Million Stock Position in Amgen Inc. $AMGN

Diversified Trust Co grew its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 8.9% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,681 shares of the medical research company’s stock after buying an additional 3,471 shares during the period. Diversified Trust Co’s holdings in Amgen were worth $12,045,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of AMGN. Legacy Investment Solutions LLC acquired a new stake in Amgen in the second quarter worth $27,000. CBIZ Investment Advisory Services LLC increased its position in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after buying an additional 85 shares in the last quarter. Evelyn Partners Investment Management LLP acquired a new stake in Amgen during the 2nd quarter worth $32,000. Howard Hughes Medical Institute bought a new position in Amgen during the second quarter worth about $32,000. Finally, Quaker Wealth Management LLC grew its stake in Amgen by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 240 shares during the period. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on AMGN shares. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, November 25th. BMO Capital Markets increased their target price on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Scotiabank began coverage on shares of Amgen in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $385.00 price target on the stock. Piper Sandler upped their price target on shares of Amgen from $342.00 to $381.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Finally, HSBC restated a “buy” rating and set a $425.00 price objective on shares of Amgen in a report on Wednesday, December 10th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $332.85.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president directly owned 7,082 shares of the company’s stock, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Murdo Gordon sold 6,879 shares of the firm’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president directly owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. 0.69% of the stock is currently owned by corporate insiders.

Amgen Price Performance

NASDAQ AMGN opened at $329.63 on Tuesday. The firm’s 50 day moving average is $323.50 and its 200-day moving average is $301.99. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. The company has a market capitalization of $177.50 billion, a PE ratio of 25.47, a price-to-earnings-growth ratio of 3.09 and a beta of 0.45. Amgen Inc. has a 12-month low of $257.05 and a 12-month high of $346.38.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The business had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. During the same quarter last year, the firm earned $5.58 earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities research analysts anticipate that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be given a dividend of $2.52 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.38. The ex-dividend date of this dividend is Friday, February 13th. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. Amgen’s payout ratio is presently 73.57%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.